Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTI-002: eftilagimod alpha plus pembrolizumab in advanced NSCLC and HNSCC
2018-001994-25Phase 2Unknown
- Sponsor
- Immutep Limited
- Start
- Jul 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of eftilagimod alpha and pembrolizumab in non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Immutep Limited. Primary endpoint: Best overall response rate. Status: unknown.
02
Drugs
eftilagimod alphapembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2018-001994-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001994-25.